Zou Jun, Xu Baisheng, Gao Hongbing, Luo Peiyue, Chen Tao, Duan Huanglin
Department of Otorhinolaryngology, The Affiliated Fengcheng Hospital of Yichun University, Fengcheng, Jiangxi, China.
Department of Urology, The First People's Hospital of Xiushui, Jiujiang, Jiangxi, China.
Front Immunol. 2024 Dec 5;15:1507355. doi: 10.3389/fimmu.2024.1507355. eCollection 2024.
Urological tumors are an important disease affecting global human health, and their pathogenesis and treatment have been the focus of medical research. With the in - depth study of microbiomics, the role of the microbiome in urological tumors has gradually attracted attention. However, the current research on tumor - associated microorganisms mostly focuses on one type or one site, and currently, there is a lack of attention to the microbiome in the immunity and immunotherapy of urological tumors. Therefore, in this paper, we systematically review the distribution characteristics of the microbiome (including microorganisms in the gut, urine, and tumor tissues) in urologic tumors, the relationship with disease prognosis, and the potential mechanisms of microbial roles in immunotherapy. In particular, we focus on the molecular mechanisms by which the microbiome at different sites influences tumor immunity through multiple "messengers" and pathways. We aim to further deepen the understanding of microbiome mechanisms in urologic tumors, and also point out the direction for the future development of immunotherapy for urologic tumors.
泌尿系统肿瘤是影响全球人类健康的重要疾病，其发病机制和治疗一直是医学研究的重点。随着微生物组学的深入研究，微生物群在泌尿系统肿瘤中的作用逐渐受到关注。然而，目前关于肿瘤相关微生物的研究大多集中在某一种类型或某一个部位，目前对于泌尿系统肿瘤免疫和免疫治疗中的微生物群缺乏关注。因此，在本文中，我们系统地综述了泌尿系统肿瘤中微生物群（包括肠道、尿液和肿瘤组织中的微生物）的分布特征、与疾病预后的关系以及微生物在免疫治疗中的潜在作用机制。特别是，我们重点关注不同部位的微生物群通过多种“信使”和途径影响肿瘤免疫的分子机制。我们旨在进一步加深对泌尿系统肿瘤中微生物群机制的理解，同时也为泌尿系统肿瘤免疫治疗的未来发展指明方向。
